Loading...
XASX4DX
Market cap115mUSD
Dec 27, Last price  
0.45AUD
1D
0.00%
1Q
-28.57%
IPO
15.38%
Name

4DMedical Ltd

Chart & Performance

D1W1MN
XASX:4DX chart
P/E
—
P/S
49.34
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.59%
Rev. gr., 5y
40.12%
Revenues
4m
+1,230.44%
252,811350,8901,925789,259695,0011,232,501216,9781,054,300282,1813,754,256
Net income
-36m
L+14.36%
-139,029-796,268-3,973,937-3,936,980-6,491,005-21,975,379-21,420,531-24,592,876-31,459,798-35,978,672
CFO
-31m
L+36.26%
-40,940-703,000-2,158,364-3,378,717-5,778,913-7,650,348-14,520,004-25,269,278-22,652,694-30,866,882
Earnings
Feb 26, 2025

Profile

4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
URL
https://4dmedical.com/
IPO date
Aug 07, 2020
Employees
131
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062015‑122014‑12
Income
Revenues
3,754
1,230.44%
282
-73.24%
1,054
385.90%
Cost of revenue
31,098
29,182
26,344
Unusual Expense (Income)
NOPBT
(27,344)
(28,900)
(25,290)
NOPBT Margin
Operating Taxes
(4,417)
323
43
Tax Rate
NOPAT
(22,927)
(29,224)
(25,333)
Net income
(35,979)
14.36%
(31,460)
27.92%
(24,593)
14.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
35,000
42,558
BB yield
Debt
Debt current
945
933
1,100
Long-term debt
9,297
9,344
11,378
Deferred revenue
718
Other long-term liabilities
15,240
186
105
Net debt
(20,365)
(59,344)
(38,681)
Cash flow
Cash from operating activities
(30,867)
(22,653)
(25,269)
CAPEX
(156)
(731)
(3,078)
Cash from investing activities
(40,040)
(1,614)
(3,501)
Cash from financing activities
31,937
42,728
(995)
FCF
(22,416)
(28,130)
(32,866)
Balance
Cash
30,606
69,576
51,115
Long term investments
45
45
Excess cash
30,418
69,607
51,107
Stockholders' equity
70,927
71,460
59,511
Invested Capital
61,588
7,178
14,706
ROIC
ROCE
EV
Common stock shares outstanding
327,079
300,014
294,508
Price
Market cap
EV
EBITDA
(23,279)
(26,335)
(23,794)
EV/EBITDA
Interest
264
7
180
Interest/NOPBT